Mavacamten and Oteseconazole: FDA Novel Drug Approvals in April 2022

There were two novel small molecules approved in April 2022: 

• mavacamten (Camzyos), an oral cardiac myosin inhibitor

• oteseconazole (Vivjoy), an oral antifungal (jump to section)

This deep dive explores each drug in more detail, including the industry context, the clinical data, the target rationale, mechanisms of action, and drug origins.

See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.